Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes

Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes

Myelodysplastic syndromes and chronic myelomonocytic leukemia are blood disorders characterized by ineffective hematopoiesis and progressive marrow failure that can transform into acute leukemia. The DNA methyltransferase inhibitor 5-azacytidine (AZA) is the most effective pharmacological option, bu...

תיאור מלא

מידע ביבליוגרפי
Main Authors:	Unnikrishnan, A, Deshpande, NP, Verma, A, Kumari, A, Richards, LA, Knezevic, K, Chandrakanthan, V, Thoms, JAI, Tursky, ML, Huang, Y, Ali, Z, Olivier, J, Galbraith, S, Kulasekararaj, AG, Tobiasson, M, Karimi, M, Pellagatti, A, Wilson, SR, Lindeman, R, Young, B, Ramakrishna, R, Arthur, C, Stark, R, Crispin, P, Curnow, J, Warburton, P, Roncolato, F, Boultwood, J, Lynch, K, Jacobsen, SEW, Mufti, GJ, Hellstrom-Lindberg, E, Wilkins, MR, MacKenzie, KL, Wong, JWH, Campbell, PJ, Pimanda, JE
פורמט:	Journal article
שפה:	English
יצא לאור:	Cell Press 2017

פריטים דומים

Myelodysplastic syndromes: moving towards personalized management
מאת: Eva Hellström-Lindberg, et al.
יצא לאור: (2020-07-01)

Spliceosome mutations: 1 plus 1 does not always equal 2
מאת: Pellagatti, A, et al.
יצא לאור: (2020)

Reduced translation of GATA1 in Diamond-Blackfan anemia.
מאת: Boultwood, J, et al.
יצא לאור: (2014)

SF3B1 mutant myelodysplastic syndrome: Recent advances
מאת: Pellagatti, A, et al.
יצא לאור: (2020)

Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
מאת: Pellagatti, A, et al.
יצא לאור: (2016)

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
מאת: Jädersten, M, et al.
יצא לאור: (2009)

Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes
מאת: Follo, M, et al.
יצא לאור: (2019)

P557: HEMATOLOGIC IMPROVEMENTS WITH IVOSIDENIB + AZACITIDINE COMPARED WITH PLACEBO + AZACITIDINE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA
מאת: H. Dohner, et al.
יצא לאור: (2022-06-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk myelodysplastic syndrome: the Phase 3, randomized, ENHANCE Study
מאת: Garcia-Manero, G, et al.
יצא לאור: (2021)

Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.
מאת: Boultwood, J, et al.
יצא לאור: (2012)

5q- syndrome.
מאת: Boultwood, J, et al.
יצא לאור: (2012)

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
מאת: Svensson, T, et al.
יצא לאור: (2014)

P556: CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA RECEIVING IVOSIDENIB + AZACITIDINE OR PLACEBO + AZACITIDINE
מאת: A. Schuh, et al.
יצא לאור: (2022-06-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): the phase 3, randomized, ENHANCE study
מאת: Garcia-Manero, G, et al.
יצא לאור: (2021)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndromes (MDS): the Phase 3, randomized, ENHANCE Study
מאת: Garcia-Manero, G, et al.
יצא לאור: (2021)

PHASE 2 STUDY OF PEVONEDISTAT + AZACITIDINE VERSUS AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES/CHRONIC MYELOMONOCYTIC LEUKEMIA OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA (NCT02610777)
מאת: L. Adès, et al.
יצא לאור: (2020-11-01)

P430: MOLECULAR CHARACTERIZATION OF CLINICAL RESPONSE IN NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE
מאת: S. de Botton, et al.
יצא לאור: (2022-06-01)

Gene expression profiling of day 7 erythroblasts from RARS before and after treatment with G-CSF
מאת: Nikpour, M, et al.
יצא לאור: (2007)

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
מאת: Pellagatti, A, et al.
יצא לאור: (2009)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
מאת: R Edlin, et al.
יצא לאור: (2010-05-01)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
מאת: R Edlin, et al.
יצא לאור: (2010-05-01)

P748: SINGLE CELL GENOTYPING OF MATCHED BONE MARROW AND PERIPHERAL BLOOD CELLS IN TREATMENT NAIVE AND AZA-TREATED MDS AND CMML
מאת: A. Schnegg-Kaufmann, et al.
יצא לאור: (2022-06-01)

MDS-197: Magrolimab + azacitidine versus azacitidine + placebo in untreated higher-risk (HR) myelodysplastic syndromes (MDS): the phase 3, randomized, ENHANCE study
מאת: Garcia-Manero, G, et al.
יצא לאור: (2021)

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes (British Journal of Haematology (2008) 142, (57-64))
מאת: Pellagatti, A, et al.
יצא לאור: (2009)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.
מאת: Pellagatti, A, et al.
יצא לאור: (2011)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
מאת: Pellagatti, A, et al.
יצא לאור: (2010)

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes.
מאת: Pellagatti, A, et al.
יצא לאור: (2008)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome
מאת: Pellagatti, A, et al.
יצא לאור: (2011)

Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
מאת: Scharenberg, C, et al.
יצא לאור: (2011)

Gene expression profiling in the myelodysplastic syndromes.
מאת: Pellagatti, A, et al.
יצא לאור: (2005)

A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes
מאת: Sara Mongiorgi, et al.
יצא לאור: (2023-02-01)

Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches
מאת: Armstrong, R, et al.
יצא לאור: (2017)

Advances in the 5q- syndrome.
מאת: Boultwood, J, et al.
יצא לאור: (2010)

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.
מאת: Pellagatti, A, et al.
יצא לאור: (2010)

The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?
מאת: Anjali Bhatt, et al.
יצא לאור: (2022-11-01)

A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine
מאת: Chiara R. Dart, et al.
יצא לאור: (2021-07-01)

NEW INSIGHTS INTO THE BIOLOGY OF REFRACTORY ANEMIA WITH RING SIDEROBLASTS (RARS) AND IDENTIFICATION OF ERYTHROID G-CSF TARGETS BY GENE EXPRESSION PROFILING
מאת: Nikpour, M, et al.
יצא לאור: (2009)

YI1 Gene expression profiling of day 7 erythroblasts from refractory anemia with ringed sideroblasts (RARS) and microarray-based identification of erythroid granulocyte-CSF (G-CSF) targets
מאת: Nikpour, M, et al.
יצא לאור: (2009)

Gene expression profiling of day 7 erythroblasts from refractory anemia with ringed sideroblasts (RARS) and microarray-based identification of erythroid granulocyte-CSF (G-CSF) targets
מאת: Nikpour, M, et al.
יצא לאור: (2009)

Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF.
מאת: Nikpour, M, et al.
יצא לאור: (2010)